Myriad Genetics Sets $785M Midpoint Revenue Outlook

The diagnostics company raised its 2026 revenue outlook midpoint as it agrees to sell its Prenatal Health testing business to Labcorp.

Updated on Nov. 7, 2026 in Healthcare

Myriad Genetics Sets $785M Midpoint Revenue Outlook

Myriad Genetics set its 2026 revenue outlook at $780 million to $790 million, with a midpoint of $785 million. The company also agreed to sell its Prenatal Health testing business to Labcorp.

Why it matters

The outlook reflects reimbursement pressure from increased zero-pay outcomes and denials, which the company is addressing through process improvements and payer-specific market access efforts. The planned sale is expected to reshape the company's growth and margin profile going forward.

Myriad's 2026 revenue outlook range is $780 million to $790 million, with the midpoint raised to $785 million. Projected revenue growth and gross margin are expected to improve by more than 1 and 5 percentage points, respectively, after the Prenatal Health sale, though the sale price was not disclosed.

The players

Myriad Genetics

Myriad Genetics is a diagnostic testing company known for hereditary cancer and prenatal genetic testing.

Labcorp

Labcorp is one of the largest clinical laboratory companies in the United States, providing diagnostic testing services nationwide.

The details

Higher revenue per test partly offsets softness in the Prenatal Health business, which is being sold to Labcorp. Reimbursement pressure stems from increased zero-pay outcomes and denials rather than lower contract rates or changes in medical policy.

2026-11-07
Outlook update published following the Labcorp sale agreement.
2026: Revenue outlook range of $780 million to $790 million set.
After the planned sale: Revenue and gross margin improvement expected.
2027: Meaningful progress in bottom-line profitability expected.

Market Landscape

The outlook reflects a broader reimbursement squeeze on U.S. diagnostic labs, where rising zero-pay claims and denials are forcing companies to reassess their testing portfolios. Myriad's planned exit from Prenatal Health, sold to Labcorp, signals consolidation among lab operators seeking margin gains in a tightening payer environment.

Patients ordering Myriad's hereditary cancer or prenatal tests may see changes in which lab handles their results once the Prenatal Health sale closes. Billing and denial patterns that drive zero-pay outcomes remain a practical concern for patients who face out-of-pocket costs.

The takeaway

Reimbursement pressure is pushing diagnostic labs to prune lower-margin lines and tighten payer relationships. Watch whether the Prenatal Health divestiture delivers the margin gains management projects in the coming year.